Repare Therapeutics (RPTX) Competitors $1.76 -0.05 (-2.76%) Closing price 04:00 PM EasternExtended Trading$1.76 +0.00 (+0.28%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RPTX vs. NGNE, LFCR, MREO, ACB, RNAC, CADL, MNPR, NMRA, LXEO, and AVIRShould you be buying Repare Therapeutics stock or one of its competitors? The main competitors of Repare Therapeutics include Neurogene (NGNE), Lifecore Biomedical (LFCR), Mereo BioPharma Group (MREO), Aurora Cannabis (ACB), Cartesian Therapeutics (RNAC), Candel Therapeutics (CADL), Monopar Therapeutics (MNPR), Neumora Therapeutics (NMRA), Lexeo Therapeutics (LXEO), and Atea Pharmaceuticals (AVIR). These companies are all part of the "pharmaceutical products" industry. Repare Therapeutics vs. Its Competitors Neurogene Lifecore Biomedical Mereo BioPharma Group Aurora Cannabis Cartesian Therapeutics Candel Therapeutics Monopar Therapeutics Neumora Therapeutics Lexeo Therapeutics Atea Pharmaceuticals Repare Therapeutics (NASDAQ:RPTX) and Neurogene (NASDAQ:NGNE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability. Which has stronger earnings & valuation, RPTX or NGNE? Neurogene has lower revenue, but higher earnings than Repare Therapeutics. Neurogene is trading at a lower price-to-earnings ratio than Repare Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRepare Therapeutics$53.48M1.41-$84.69M-$2.58-0.68Neurogene$930K291.54-$75.14M-$4.31-4.41 Does the media favor RPTX or NGNE? In the previous week, Neurogene had 1 more articles in the media than Repare Therapeutics. MarketBeat recorded 2 mentions for Neurogene and 1 mentions for Repare Therapeutics. Repare Therapeutics' average media sentiment score of 1.89 beat Neurogene's score of 1.23 indicating that Repare Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Repare Therapeutics Very Positive Neurogene Positive Which has more volatility and risk, RPTX or NGNE? Repare Therapeutics has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, Neurogene has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500. Is RPTX or NGNE more profitable? Neurogene's return on equity of -33.33% beat Repare Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Repare TherapeuticsN/A -78.25% -66.85% Neurogene N/A -33.33%-30.34% Do insiders and institutionals have more ownership in RPTX or NGNE? 85.1% of Repare Therapeutics shares are held by institutional investors. Comparatively, 52.4% of Neurogene shares are held by institutional investors. 11.5% of Repare Therapeutics shares are held by company insiders. Comparatively, 11.6% of Neurogene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts rate RPTX or NGNE? Repare Therapeutics presently has a consensus target price of $4.50, suggesting a potential upside of 155.68%. Neurogene has a consensus target price of $46.17, suggesting a potential upside of 142.98%. Given Repare Therapeutics' higher possible upside, equities research analysts clearly believe Repare Therapeutics is more favorable than Neurogene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Repare Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Neurogene 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 SummaryNeurogene beats Repare Therapeutics on 9 of the 15 factors compared between the two stocks. Get Repare Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RPTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RPTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RPTX vs. The Competition Export to ExcelMetricRepare TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$75.61M$3.13B$5.79B$10.15BDividend YieldN/A2.32%5.69%4.60%P/E Ratio-0.6821.3074.5925.92Price / Sales1.41257.21453.5485.33Price / CashN/A45.3337.0859.91Price / Book0.499.6112.156.29Net Income-$84.69M-$53.29M$3.28B$270.77M7 Day Performance4.14%0.28%0.99%3.36%1 Month Performance12.82%8.91%7.21%6.41%1 Year Performance-41.33%13.14%63.07%28.24% Repare Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RPTXRepare Therapeutics2.8694 of 5 stars$1.76-2.8%$4.50+155.7%-35.6%$75.61M$53.48M-0.68180Positive NewsNGNENeurogene2.0425 of 5 stars$19.45-2.5%$46.17+137.4%-49.0%$284.73M$930K-4.5190Positive NewsLFCRLifecore Biomedical1.1801 of 5 stars$7.29-3.2%$8.00+9.7%+60.2%$281.68M$128.87M-5.56690Positive NewsMREOMereo BioPharma Group2.4241 of 5 stars$1.79+1.1%$7.40+313.4%-60.9%$281.43M$10M-25.5740Positive NewsACBAurora Cannabis0.5309 of 5 stars$4.84-1.4%N/A-12.1%$277.19M$246.72M-25.471,130RNACCartesian Therapeutics2.4488 of 5 stars$10.19-4.2%$40.00+292.5%-35.8%$276.66M$38.91M-0.1964Positive NewsCADLCandel Therapeutics2.3513 of 5 stars$5.10+2.0%$20.00+292.2%-25.5%$274.48M$120K-7.3960MNPRMonopar Therapeutics3.3343 of 5 stars$41.48-6.2%$69.57+67.7%+1,886.3%$272.77MN/A-12.4610Analyst ForecastNMRANeumora Therapeutics2.9147 of 5 stars$1.66-1.2%$7.14+330.3%-85.4%$272.07MN/A-1.06108News CoveragePositive NewsLXEOLexeo Therapeutics2.7042 of 5 stars$5.25+4.6%$15.33+192.1%-49.4%$271.09M$650K-1.6158Positive NewsAVIRAtea Pharmaceuticals2.079 of 5 stars$3.25-3.6%$6.00+84.6%-10.1%$267.43MN/A-2.0270Short Interest ↑ Related Companies and Tools Related Companies Neurogene Alternatives Lifecore Biomedical Alternatives Mereo BioPharma Group Alternatives Aurora Cannabis Alternatives Cartesian Therapeutics Alternatives Candel Therapeutics Alternatives Monopar Therapeutics Alternatives Neumora Therapeutics Alternatives Lexeo Therapeutics Alternatives Atea Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RPTX) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored6-Figure Target for BTC by 2025Trump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredWall Street laughed at Trump’s “Smart Dollar.” Now they’re all in."THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repare Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Repare Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RPTX Stock Alerts